RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.27
+1.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5M | 2.8M | 38.9M | 26.0M | 110.8M |
| Cost of Revenue | 12.8M | — | — | — | 2.0M |
| Gross Profit | (11.3M) | 2.8M | 38.9M | 26.0M | 108.7M |
| Operating Expenses | |||||
| R&D Expense | 68.4M | 58.0M | 45.1M | 71.3M | 72.4M |
| SG&A Expense | 31.8M | 31.5M | 30.1M | 40.5M | 23.9M |
| General & Admin Expense | 30.6M | 31.5M | 30.1M | 40.5M | 23.9M |
| Selling & Marketing Expense | 1.1M | — | — | — | — |
| Other Expenses | (12.8M) | — | 7.6M | 710.0K | (2.0M) |
| Total Operating Expenses | 87.3M | 89.5M | 82.8M | 112.4M | 94.2M |
| Cost and Expenses | 100.1M | 89.5M | 82.8M | 112.4M | 96.2M |
| Operating Income (EBIT) | (98.7M) | (86.7M) | (43.9M) | (86.4M) | 14.5M |
| Non-Operating | |||||
| Interest Income | 4.9M | 6.6M | 7.4M | 5.0M | — |
| Interest Expense | 852.0K | — | — | 2.8M | 3.0M |
| Net Interest Income | 4.1M | 6.6M | 7.4M | 2.1M | (3.0M) |
| Other Non-Op Income/Expense | (62.4M) | (52.8M) | (33.2M) | (152.3M) | 20.2M |
| Non-Operating Income (excl Interest) | 61.6M | 52.8M | 33.2M | 149.5M | (23.3M) |
| EBT (Pre-Tax Income) | (161.1M) | (139.5M) | (77.1M) | (238.7M) | 34.8M |
| Income Tax Expense | (9.2M) | (9.2M) | 287.0K | (19.0M) | (609.0K) |
| Bottom Line | |||||
| Net Income | (153.9M) | (130.3M) | (77.4M) | (219.7M) | 35.4M |
| Earnings from Cont. Ops | (151.9M) | (130.3M) | (77.4M) | (219.7M) | 35.4M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (153.9M) | (130.3M) | (77.9M) | (257.3M) | 14.5M |
| Per Share | |||||
| Basic EPS | ($5.93) | ($5.02) | ($3.29) | ($49.76) | $7.33 |
| Diluted EPS | ($5.84) | ($5.02) | ($3.29) | ($49.76) | $3.00 |
| Revenue Per Share | $0.05 | $0.11 | $1.64 | $5.03 | $27.55 |
| Shares | |||||
| Basic Shares Outstanding | 29.5M | 26.0M | 23.7M | 5.2M | 4.0M |
| Diluted Shares Outstanding | 29.9M | 26.0M | 23.7M | 5.2M | 4.1M |
| Profitability Metrics | |||||
| EBITDA | (157.6M) | (136.5M) | (76.0M) | (235.0M) | 39.8M |
| D&A | 2.6M | 3.0M | 1.2M | 843.0K | 2.0M |
| EBIT | (160.2M) | (139.5M) | (77.1M) | (235.9M) | 37.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026